Italia markets close in 23 minutes
FTSE MIB
34.846,51 -552,31 (-1,56%) Dow Jones
40.046,32 +42,73 (+0,11%) Nasdaq
16.788,30 +102,34 (+0,61%) Nikkei 225
39.069,68 +282,30 (+0,73%) Petrolio
79,98 -0,08 (-0,10%) Bitcoin EUR
61.611,42 +7,43 (+0,01%)
NVCR Jan 2025 5.000 call
OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
In data: 12:24PM EDT. Mercato aperto.
| Chiusura precedente | 9,00 |
| Aperto | 9,00 |
| Denaro | 4,10 |
| Lettera | 14,10 |
| Prezzo d'esercizio | 5,00 |
| Scadenza | 2025-01-17 |
| Min-Max giorno | 9,00 - 9,00 |
| Contratto - Min-Max | N/D |
| Volume | |
| Open Interest | N/D |
GlobeNewswireZai Lab and Novocure Announce LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
Tumor Treating Fields therapy together with standard of care provided a statistically significant and clinically meaningful 3-month improvement in median overall survival versus standard of care with no added systemic toxicities Tumor Treating Fields therapy together with immune checkpoint inhibitors resulted in an unprecedented 8-month improvement in median overall survival LUNAR is the first phase 3 clinical trial in more than seven years to show a significant extension in overall survival in
© 2024 Yahoo. Tutti i diritti riservati.